Zoledronic acid inhibits the pentose phosphate pathway through attenuating the Ras-TAp73-G6PD axis in bladder cancer cells

Molecular Medicine Reports

Volumn 12, Issue 3, 2015, Pages 4620-4625

  Wang, Xiaolin ^a,b   Wu, Guang ^c   Cao, Guangxin ^b   Yang, Lei ^b   Xu, Haifei ^b   Huang, Jian ^b   Hou, Jianquan ^a  

^a SOOCHOW UNIVERSITY   (China)

^b Nantong Tumor Hospital   (China)

^c First People's Hospital   (China)

Author keywords

Glucose 6 phosphate dehydrogenase; Pentose phosphate pathway; Ras; TAp73; Zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAS PROTEIN; TAP73 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DNA BINDING PROTEIN; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; MAPK1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; ENZYME PHOSPHORYLATION; GLUCOSE INTAKE; HUMAN; HUMAN CELL; PENTOSE PHOSPHATE CYCLE; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; BLADDER; CELL SURVIVAL; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BONE DENSITY CONSERVATION AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DIPHOSPHONATES; DNA-BINDING PROTEINS; ENZYME INHIBITORS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSEPHOSPHATE DEHYDROGENASE; HEK293 CELLS; HUMANS; IMIDAZOLES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NUCLEAR PROTEINS; ORGAN SPECIFICITY; PENTOSE PHOSPHATE PATHWAY; PROTEIN STABILITY; RAS PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER;

EID: 84935497864     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3995     Document Type: Article

References (30)

1. Parkin DM: The global burden of urinary bladder cancer. Scand J Urol Nephrol (Suppl):12-20, 2008.
2. Noon A P, Albertsen PC, Thomas F, Rosario DJ and Catto JW: Competing mortality in patients diagnosed with bladder cancer: Evidence of undertreatment in the elderly and female patients. Br J Cancer 108:1534-1540, 2013.
3. Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G, Kanakis I and Karamanos NK: The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 125:1705-1709, 2009.
4. Hirata H, Hinoda Y, Ueno K, Shahryari V, Tabatabai ZL and Dahiya R: MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis 33:41-48, 2012.
5. Alcaraz A, González-López R, Morote J, De La Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, et al: Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. Br J Cancer 109:121-130, 2013.
6. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I and Nazmy M: A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15:382-389, 2010.
7. Saad F and Eastham JA: Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol (37 Suppl 1):S38-S44, 2010.
8. Gouin F, Ory B, Rédini F and Heymann D: Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 119:980-984, 2006.
9. Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye JC and Séronie-Vivien S: Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 6:60, 2006.
10. Koto K, Murata H, Kimura S, Sawai Y, Horie N, Matsui T, Ryu K, Ashihara E, Maekawa T, Kubo T, et al: Zoledronic acid significantly enhances radiation-induced apoptosis against human fibrosarcoma cells by inhibiting radioadaptive signaling. Int J Oncol 42:525-534, 2013.
11. Rowinsky EK, Windle JJ and Von Hoff DD: Ras protein farne-syltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17:3631-3652, 1999.
12. Wei J, Zaika E and Zaika A: p53 Family: Role of protein isoforms in human cancer. J Nucleic Acids 2012:687359, 2012.
13. Stiewe T and Putzer BM: Role of p73 in malignancy: Tumor suppressor or oncogene? Cell Death Differ 9:237-245, 2002.
14. Lunghi P, Costanzo A, Mazzera L, Rizzoli V, Levrero M and Bonati A: The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. Clin Cancer Res 15:6 495-6502, 2009.
15. Tomkova K, Belkhiri A, El-Rifai W and Zaika AI: p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. Cancer Res 64:6390-6393, 2004.
16. Zaika AI and El-Rifai W: The role of p53 protein family in gastrointestinal malignancies. Cell Death Differ 13:935-940, 2006.
17. Conforti F, Yang AL, Agostini M, Rufini A, Tucci P, Nicklison-Chirou M V, Grespi F, Velletri T, Knight RA, Melino G, et al: Relative expression of TAp73 and ΔNp73 isoforms. Aging (Albany NY) 4:202-205, 2012.
18. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou M V, Conforti F, Velletri T, Mastino A, Mak T W, et al: p73 in Cancer. Genes Cancer 2:491-502, 2011.
19. Lin D, Cui Z, Kong L, Cheng F, Xu J and Lan F: p73 participates in WWOX-mediated apoptosis in leukemia cells. Int J Mol Med 31:8 49-854, 2013.
20. Grob TJ, Novak U, Maisse C, Barcaroli D, Lüthi AU, Pirnia F, Hügli B, Graber HU, De Laurenzi V, Fey M F, et al: Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 8:1213-1223, 2001.
21. Samudio I, Fiegl M and Andreeff M: Mitochondrial uncoupling and the Warburg effect: Molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 69:2163-2166, 2009.
22. Cairns RA, Harris IS and Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer 11:85-95, 2011.
23. Jones RG and Thompson CB: Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev 23:537-548, 2009.
24. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M and Yang X: p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 13:310-316, 2011.
25. Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ, Mak TW, Wu M and Yang X: TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat Cell Biol 15:991-1000, 2013.
26. Fernandez-Garcia B, Vaqué JP, Herreros-Villanueva M, Marques-Garcia F, Castrillo F, Fernandez-Medarde A, León J and Marín MC: p73 cooperates with Ras in the activation of MAP kinase signaling cascade. Cell Death Differ 14:254-265, 2007.
27. Chang J, Wang W, Zhang H, Hu Y and Yin Z: Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells. Oncol Lett 4:299-304, 2012.
28. Ohtsuka Y, Manabe A, Kawasaki H, Hasegawa D, Zaike Y, Watanabe S, Tanizawa T, Nakahata T and Tsuji K: RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro. Blood 106:3134-3141, 2005.
29. Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, Bosia A, Ghigo D and Massaia M: Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS One 8:e60975, 2013.
30. Cairns RA, Harris I, McCracken S and Mak TW: Cancer cell metabolism. Cold Spring Harb Symp Quant Biol 76:299-311, 2011.